{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:04:59Z","timestamp":1781305499219,"version":"3.54.1"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"BIOASTER"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The aim of this study was to identify and determine the MICs of 13 antifungal drugs, including the novel agents ibrexafungerp, manogepix and rezafungin, against 22 laboratory reference strains from 14 different Candida spp. and allied yeast genera using the EUCAST, CLSI and Sensititre\u2122 YeastOne\u2122 (SYO) methods.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Complete agreement between molecular and proteomics methods was observed for identification. The compounds with the greatest in vitro activity, as indicated by the lowest geometric mean MIC (GM), were manogepix (GM: 0.01), isavuconazole (GM: 0.05) and rezafungin (GM: 0.03\u20130.07). The overall essential agreement (EA) (within \u00b10 to \u00b12 2-fold dilutions) between the reference methods, EUCAST and CLSI, was 95%, with results ranging from 82% (ibrexafungerp) to 100% (amphotericin B, anidulafungin, fluconazole, 5-flucytosine and micafungin). Regarding EA for EUCAST and CLSI compared with SYO, values were 91% and 89%, respectively. Nevertheless, when the MIC values were transformed into log2, significant differences were observed (e.g. fluconazole, ibrexafungerp and 5-flucytosine). At the species level, Candidozyma auris and Candida duobushaemulonii exhibited the highest number of cases with significant differences when comparing the three techniques for each antifungal.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The high EA observed reinforces the reliability of EUCAST, CLSI and SYO in guiding antifungal therapy. However, the differences in EA, particularly for ibrexafungerp and 5-flucytosine, highlight the importance of continued evaluation of these methodologies to ensure consistency. Given that antifungal susceptibility testing plays a critical role in treatment decisions, understanding these variations is essential to prevent potential misclassification of susceptibility profiles, which could impact clinical outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlaf040","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T07:30:12Z","timestamp":1742369412000},"source":"Crossref","is-referenced-by-count":14,"title":["Identification and antifungal susceptibility patterns of reference yeast strains to novel and conventional agents: a comparative study using CLSI, EUCAST and Sensititre YeastOne methods"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2129-1399","authenticated-orcid":false,"given":"Andres","family":"Ceballos-Garzon","sequence":"first","affiliation":[{"name":"BIOASTER Research Institute , 40 avenue Tony Garnier, Lyon F-69007 ,","place":["France"]},{"name":"Translational Microbiology and Emerging Diseases Research Group (MICROS), School of Medicine and Health Sciences, Universidad del Rosario , Bogot\u00e1 ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Holzapfel","sequence":"additional","affiliation":[{"name":"BIOASTER Research Institute , 40 avenue Tony Garnier, Lyon F-69007 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Welsch","sequence":"additional","affiliation":[{"name":"BIOASTER Research Institute , 40 avenue Tony Garnier, Lyon F-69007 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derry","family":"Mercer","sequence":"additional","affiliation":[{"name":"BIOASTER Research Institute , 40 avenue Tony Garnier, Lyon F-69007 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"2025031907272515000_dlaf040-B1","doi-asserted-by":"publisher","first-page":"e32278","DOI":"10.1371\/journal.pone.0032278","article-title":"Antifungal susceptibility profiles of 1698 yeast reference strains revealing potential emerging human pathogens","volume":"7","author":"Desnos-Ollivier","year":"2012","journal-title":"PLoS One"},{"key":"2025031907272515000_dlaf040-B2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41579-022-00720-1","article-title":"Tackling the emerging threat of antifungal resistance to human health","volume":"20","author":"Fisher","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"2025031907272515000_dlaf040-B3","doi-asserted-by":"publisher","first-page":"ofab444","DOI":"10.1093\/ofid\/ofab444","article-title":"Antifungal susceptibility testing: a primer for clinicians","volume":"8","author":"Wiederhold","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025031907272515000_dlaf040-B4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/1567-1364.12068","article-title":"Clinical isolates and laboratory reference Candida species and strains have varying abilities to form biofilms","volume":"13","author":"Alnuaimi","year":"2013","journal-title":"FEMS Yeast Res"},{"key":"2025031907272515000_dlaf040-B5","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1128\/JCM.42.8.3475-3482.2004","article-title":"Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species","volume":"42","author":"Odds","year":"2004","journal-title":"J Clin Microbiol"},{"key":"2025031907272515000_dlaf040-B6","doi-asserted-by":"publisher","first-page":"106558","DOI":"10.1016\/j.ijantimicag.2022.106558","article-title":"Head-to-head comparison of CLSI, EUCAST, Etest and Vitek2 results for Candida auris susceptibility testing","volume":"59","author":"Ceballos-Garzon","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2025031907272515000_dlaf040-B7","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1080\/14787210.2020.1760841","article-title":"Antifungal susceptibility testing in Candida species: current methods and promising new tools for shortening the turnaround time","volume":"18","author":"Knabl","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025031907272515000_dlaf040-B8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ram.2021.02.002","article-title":"Usefulness of the sensititre YeastOne\u00ae panel to detect Candida species resistant to antifungal drugs","volume":"54","author":"C\u00f3rdoba","year":"2022","journal-title":"Rev Argent Microbiol"},{"key":"2025031907272515000_dlaf040-B9","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1128\/JCM.43.8.3884-3889.2005","article-title":"International and multileft comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole","volume":"43","author":"Espinel-Ingroff","year":"2005","journal-title":"J Clin Microbiol"},{"key":"2025031907272515000_dlaf040-B10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.diagmicrobio.2014.03.004","article-title":"Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp","volume":"79","author":"Pfaller","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2025031907272515000_dlaf040-B11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ijantimicag.2019.02.005","article-title":"Outbreak of Candida auris in Spain: a comparison of antifungal activity by three methods with published data","volume":"53","author":"Ruiz-Gait\u00e1n","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2025031907272515000_dlaf040-B12","doi-asserted-by":"publisher","first-page":"ofac559","DOI":"10.1093\/ofid\/ofac559","article-title":"Fungal nomenclature: managing change is the name of the game","volume":"10","author":"Kidd","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025031907272515000_dlaf040-B13","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41579-023-00960-9","article-title":"The rapid emergence of antifungal-resistant human-pathogenic fungi","volume":"21","author":"Lockhart","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"2025031907272515000_dlaf040-B14","doi-asserted-by":"publisher","first-page":"1136217","DOI":"10.3389\/fcimb.2023.1136217","article-title":"Emergence and circulation of azole-resistant C. albicans, C. auris and C. parapsilosis bloodstream isolates carrying Y132F, K143R or T220L Erg11p substitutions in Colombia","volume":"13","author":"Ceballos-Garzon","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"2025031907272515000_dlaf040-B15","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1128\/JCM.40.8.2860-2865.2002","article-title":"Rapid identification of pathogenic fungi directly from cultures by using multiplex PCR","volume":"40","author":"Luo","year":"2002","journal-title":"J Clin Microbiol"},{"key":"2025031907272515000_dlaf040-B16","first-page":"315","volume-title":"PCR Protocols: A Guide to Methods and Applications","author":"White","year":"1990"},{"key":"2025031907272515000_dlaf040-B17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12866-019-1482-y","article-title":"Comparison between MALDI-TOF MS and MicroScan in the identification of emerging and multidrug resistant yeasts in a fourth-level hospital in Bogot\u00e1, Colombia","volume":"19","author":"Ceballos-Garz\u00f3n","year":"2019","journal-title":"BMC Microbiol"},{"key":"2025031907272515000_dlaf040-B18","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts\u2014Fourth Edition: M27","author":"CLSI","year":"2017"},{"key":"2025031907272515000_dlaf040-B19","author":"EUCAST"},{"key":"2025031907272515000_dlaf040-B20","volume-title":"Performance Standards for Antifungal Susceptibility Testing of Yeast. 3rd ed. CLSI Supplement M27M44S","author":"CLSI","year":"2022"},{"key":"2025031907272515000_dlaf040-B21","author":"EUCAST"},{"key":"2025031907272515000_dlaf040-B22","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1128\/JCM.02316-09","article-title":"Comparison of the Vitek 2 antifungal susceptibility system with the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) Broth Microdilution Reference Methods and with the Sensititre YeastOne and Etest techniques for in vitro detection of antifungal resistance in yeast isolates","volume":"48","author":"Cuenca-Estrella","year":"2010","journal-title":"J Clin Microbiol"},{"key":"2025031907272515000_dlaf040-B23","doi-asserted-by":"publisher","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025031907272515000_dlaf040-B24","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1128\/microbiolspec.funk-0002-2016","article-title":"Antifungal drugs: the current armamentarium and development of new agents","volume":"4","author":"Robbins","year":"2017","journal-title":"Microbiol Spectr"},{"key":"2025031907272515000_dlaf040-B25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/cid\/ciw664","article-title":"Home environment as a source of life-threatening azole-resistant Aspergillus fumigatus in immunocompromised patients","volume":"64","author":"Lavergne","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"2025031907272515000_dlaf040-B26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0213-005X(13)70115-0","article-title":"Antifungal susceptibility testing in yeasts. Update and novelties","volume":"31","author":"Cuenca-Estrella","year":"2013","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2025031907272515000_dlaf040-B27","doi-asserted-by":"publisher","first-page":"e00485-17","DOI":"10.1128\/AAC.00485-17","article-title":"Comparison of EUCAST and CLSI reference microdilution mics of eight antifungal compounds for Candida auris and associated tentative epidemiological cutoff values","volume":"61","author":"Arendrup","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031907272515000_dlaf040-B28","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/mmy\/myz083","article-title":"Ibrexafungerp: a novel oral glucan synthase inhibitor","volume":"58","author":"Davis","year":"2020","journal-title":"Med Mycol"},{"key":"2025031907272515000_dlaf040-B29","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1093\/jac\/dks466","article-title":"Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)","volume":"68","author":"Pfaller","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2025031907272515000_dlaf040-B30","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1128\/JCM.39.2.525-532.2001","article-title":"Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp","volume":"39","author":"Cuenca-Estrella","year":"2001","journal-title":"J Clin Microbiol"},{"key":"2025031907272515000_dlaf040-B31","doi-asserted-by":"publisher","first-page":"e02136-19","DOI":"10.1128\/AAC.02136-19","article-title":"In vitro activity of ibrexafungerp (SCY-078) against Candida auris isolates as determined by EUCAST methodology and comparison with activity against C. albicans and C. glabrata and with the activities of six comparator agents","volume":"64","author":"Arendrup","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031907272515000_dlaf040-B32","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3390\/jof8101106","article-title":"EUCAST ibrexafungerp MICs and wild-type upper limits for contemporary Danish yeast isolates","volume":"8","author":"J\u00f8rgensen","year":"2022","journal-title":"J Fungi"},{"key":"2025031907272515000_dlaf040-B33","doi-asserted-by":"publisher","first-page":"e00562-21","DOI":"10.1128\/aac.00562-21","article-title":"In vitro Ph activity of ibrexafungerp against fluconazole-susceptible and -resistant candida isolates from women with vulvovaginal candidiasis","volume":"8","author":"Sobel","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031907272515000_dlaf040-B34","doi-asserted-by":"publisher","first-page":"906563","DOI":"10.3389\/fcimb.2022.906563","article-title":"In vitro antifungal activity of ibrexafungerp (SCY-078) against contemporary blood isolates from medically relevant species of Candida: a European study","volume":"12","author":"Quind\u00f3s","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"2025031907272515000_dlaf040-B35","doi-asserted-by":"publisher","first-page":"e0244921","DOI":"10.1128\/jcm.02449-21","article-title":"Evaluation of rezafungin provisional CLSI clinical breakpoints and epidemiological cutoff values tested against a worldwide collection of contemporaneous invasive fungal isolates (2019 to 2020)","volume":"60","author":"Carvalhaes","year":"2022","journal-title":"J Clin Microbiol"},{"key":"2025031907272515000_dlaf040-B36","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1128\/AAC.00291-11","article-title":"In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds","volume":"55","author":"Miyazaki","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031907272515000_dlaf040-B37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jgar.2021.04.012","article-title":"Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018\u20132019)","volume":"26","author":"Pfaller","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2025031907272515000_dlaf040-B38","doi-asserted-by":"publisher","first-page":"e00656-20","DOI":"10.1128\/AAC.00656-20","article-title":"Manogepix (APX001A) in vitro activity against Candida auris: head-to-head comparison of EUCAST and CLSI MICs","volume":"64","author":"Arendrup","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031907272515000_dlaf040-B39","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3906\/sag-1909-97","article-title":"Comparison of the Sensititre YeastOne antifungal method with the CLSI M27-A3 reference method to determine the activity of antifungal agents against clinical isolates of Candida spp","volume":"50","author":"Altinba\u015f","year":"2020","journal-title":"Turk J Med Sci"},{"key":"2025031907272515000_dlaf040-B40","doi-asserted-by":"publisher","first-page":"e0443122","DOI":"10.1128\/spectrum.04431-22","article-title":"Overestimation of amphotericin B resistance in Candida auris with Sensititre YeastOne antifungal susceptibility testing: a need for adjustment for correct interpretation","volume":"11","author":"Siopi","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2025031907272515000_dlaf040-B41","author":"CLSI"},{"key":"2025031907272515000_dlaf040-B42","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.riam.2017.11.001","article-title":"Evaluation of two commercial methods for the susceptibility testing of Candida species: Vitek 2\u00ae and Sensititre YeastOne\u00ae","volume":"35","author":"Siqueira","year":"2018","journal-title":"Rev Iberoam Micol"},{"key":"2025031907272515000_dlaf040-B43","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3390\/jof7110909","article-title":"Molecular mechanisms of 5-fluorocytosine resistance in yeasts and filamentous fungi","volume":"7","author":"Delma","year":"2021","journal-title":"J Fungi"},{"key":"2025031907272515000_dlaf040-B44","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.1128\/AAC.01519-13","article-title":"Interlaboratory variability of Caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?","volume":"57","author":"Espinel-Ingroff","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031907272515000_dlaf040-B45","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/jof7050356","article-title":"Comparison of two commercial colorimetric broth microdilution tests for Candida susceptibility testing: Sensititre YeastOne versus MICRONAUT-AM","volume":"7","author":"Philips","year":"2021","journal-title":"J Fungi"},{"key":"2025031907272515000_dlaf040-B46","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1128\/JCM.00493-08","article-title":"Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin","volume":"46","author":"Pfaller","year":"2008","journal-title":"J Clin Microbiol"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/2\/dlaf040\/62450648\/dlaf040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/2\/dlaf040\/62450648\/dlaf040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T07:30:19Z","timestamp":1742369419000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlaf040\/8086476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlaf040","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,4]]},"article-number":"dlaf040"}}